Characteristics of patients and prognostic factors for progression of asymptomatic myeloma in 3 series
| . | Wisloff et al36 . | Dimopoulos et al30 . | Facon et al37 . |
|---|---|---|---|
| No. of patients | 71 | 95 | 91 |
| Lytic lesions (%) | 15 | 18 | 4 |
| Median time to progression (mo) | 26 | 26 | 48 |
| Adverse prognostic factors | |||
| Bone lesions | Yes | Yes | Yes |
| Bone marrow plasmacytosis | Yes | No | Yes |
| Serum monoclonal protein | No | Yes | Yes |
| Urinary protein (Bence Jones) | No | Yes | No |
| Mild anemia | No | No | Yes |
| . | Wisloff et al36 . | Dimopoulos et al30 . | Facon et al37 . |
|---|---|---|---|
| No. of patients | 71 | 95 | 91 |
| Lytic lesions (%) | 15 | 18 | 4 |
| Median time to progression (mo) | 26 | 26 | 48 |
| Adverse prognostic factors | |||
| Bone lesions | Yes | Yes | Yes |
| Bone marrow plasmacytosis | Yes | No | Yes |
| Serum monoclonal protein | No | Yes | Yes |
| Urinary protein (Bence Jones) | No | Yes | No |
| Mild anemia | No | No | Yes |